Progesterone News and Research

RSS

New research may help identify patients most likely to benefit from cisplatin treatment

Researchers at the Massachusetts General Hospital (MGH) Cancer Center have identified a subgroup of hard-to-treat breast cancers that may be sensitive to the drug cisplatin, rarely used in the treatment of breast tumors.

20 Apr 2007

Factors that dictate risk of developing primary or secondary cancer

Every day, people make assumptions, educated and not, about their risk for developing cancer.

18 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

Breastfeeding reduces risk of invasive breast cancer

Breastfeeding can offset the increased risk of invasive breast cancer for women who had their first full-term pregnancy after the age of 25, a study led by researchers at the University of Southern California (USC) suggests.

17 Apr 2007

Triple negative breast cancers more common among women who are African American and Hispanic, under 40 years old

So-called "triple negative" breast cancers, tumors that do not contain any of three significant tumor markers, are aggressive, deadly cancers that affect young, poor minority women, according to a new study.

2 Apr 2007

Maternal beef consumption associated with lower sperm concentration

New research has shown that women who ate a lot of beef while pregnant had sons who were more likely to suffer from poor sperm quality as adults, and it suggests that the growth promoters used in cattle may play a role in these men's reduced fertility.

2 Apr 2007

Natural family planning as effective as the pill

According to the latest research a system of natural family planning is just as effective as the contraceptive pill.

22 Feb 2007

High-dose progesterone treatment helps at-risk pregnant women avoid premature delivery

In this study, 45 women who experienced premature labor (before 37 weeks gestation) were randomly divided into treatment and observation groups. The treatment group received twice-weekly 341-mg doses of progesterone until week 36.

11 Feb 2007

Selective marker found to indicate aggressive form of breast cancer

Researchers have linked a structural protein called nestin to a particularly deadly form of breast cancer, identifying a new biomarker that could lead to earlier detection and better treatment.

16 Jan 2007

Mifepristone offers hope for breast cancer victims

A team of scientists have discovered some unexpected benefits with the abortion pill RU486 (Mifepristone).

4 Dec 2006

Food can have an impact in preventing cancer

With cancer, researchers don't believe "you are what you eat"; that disease is always a direct result of what is, or what isn't, on your dinner plate.

14 Nov 2006

Confusion abounds on how to treat the menopause

The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.

25 Oct 2006

Contraceptive options in the U.S. examined

The New York Times on Tuesday examined contraceptive options in the U.S., where 60% of unplanned pregnancies occur among women who use contraception.

17 Oct 2006

Progesterone improves outcomes for victims of traumatic brain injury

A new study suggests that giving progesterone to victims with Traumatic Brain Injury (TBI) shortly following brain injury may reduce the risk of death and the degree of disability, and appears to be safe.

3 Oct 2006

March of Dimes urges FDA to approve Gestiva

The March of Dimes has urged Food and Drug Administration officials to promptly approve a commercial progesterone therapy that appears to prevent some premature births.

30 Aug 2006

FDA advisory panel recommends approval of experimental preterm labor prevention drug

An FDA advisory committee on Tuesday voted 13-8 that clinical trial data regarding Adeza's experimental preterm labor prevention drug Gestiva was adequate to approve the drug, Dow Jones reports (Corbett Dooren, Dow Jones, 8/29).

30 Aug 2006

FDA questions effectiveness of Gestiva at preventing preterm labor

FDA in a review of Adeza's experimental preterm labor prevention drug Gestiva said the drug seems to reduce deliveries before 37 weeks' gestation but not births before 32 or 35 weeks' gestation, according to documents posted Monday on the agency's Web site.

30 Aug 2006